Radiomic and clinical data integration using machine learning predict the efficacy of anti-PD-1 antibodies-based combinational treatment in advanced breast cancer: a multicentered... by Ying Wang, Ying Lin, Xiaohui Duan, Jieqiong Liu, Herui Yao, Yunfang Yu, Jianli Zhao, Zhixian Sun, Zhongyu Yuan, Yujie Tan

“…Here we aim to develop a radiomics model that could accurately predict response of ICIs for patients with advanced breast cancer (ABC).Methods Pretreatment contrast-enhanced CT (CECT) image and clinicopathological features of 240 patients with ABC who underwent ICIs-based treatment in three academic hospitals from February 2018 to January 2022 were assigned into a training cohort and an independent validation cohort. …”
Get full text

Synergistic efficacy of PI3Kδ inhibitor with anti-PD-1 mAbs in immune-humanized PDX model of endocrine resistance hormone receptor-positive advanced breast cancer by Yingjue Li, Yiwen Li, Yu Yang, Yuwei Deng, Xiangdong Ni, Bochen Zhao, Zhaoqi Yan, Wen He, Yixin Li, Shuhui Li, Linbo Liu, Dan Lu

“…Purpose: Endocrine resistance hormone receptor-positive (HR+) advanced breast cancer (ABC) is generally insensitive to immunecheckpoint inhibitors (ICIs). …”
Get full text

PTPRC promoted CD8+ T cell mediated tumor immunity and drug sensitivity in breast cancer: based on pan-cancer analysis and artificial intelligence modeling of immunogenic cell deat... by Pengping Li, Wei Wang, Shaowen Wang, Guodong Cao, Tonghe Pan, Yuqing Huang, Hong Wan, Hong Wan, Weijun Zhang, Yate Huang, Haigang Jin, Zhenyu Wang

“…Through in vitro experiments, intracellular down-regulation of PTPRC enhanced paclitaxel tolerance in triple breast cancer (TNBC) cell lines. Meanwhile, the expression level of PTPRC was positively correlated with CD8+ T cell infiltration. …”
Get full text

Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4⁺ T Cells by Reem Saleh, Salman M Toor, Sarah Khalaf, Eyad Elkord

“…Triple negative breast cancer (TNBC) is the most aggressive breast cancer subtype, and it exhibits resistance to common breast cancer therapies. …”
Get full text

Intratumoral heterogeneity after targeted therapy in murine cancer models with differing degrees of malignancy by M. Gerwing, E. Hoffmann, C. Geyer, A. Helfen, B. Maus, R. Schinner, L. Wachsmuth, W. Heindel, M. Eisenblaetter, C. Faber, M. Wildgruber

“…The aim of this study was to evaluate changes in tumor composition after targeted therapy in murine models of breast cancer with differing degrees of malignancy via non-invasive magnetic resonance imaging (MRI). …”
Get full text

PD-L1-Positive High-Grade Triple-Negative Breast Cancer Patients Respond Better to Standard Neoadjuvant Treatment—A Retrospective Study of PD-L1 Expression in Relation to Different... by Olga Stanowska, Olga Kuczkiewicz-Siemion, Małgorzata Dębowska, Wojciech P. Olszewski, Agnieszka Jagiełło-Gruszfeld, Andrzej Tysarowski, Monika Prochorec-Sobieszek

“…Immune-checkpoint inhibitors (ICI) are showing promising results in a subset of breast cancer patients in both neo- and adjuvant settings. …”
Get full text

An IL‐12‐Based Nanocytokine Safely Potentiates Anticancer Immunity through Spatiotemporal Control of Inflammation to Eradicate Advanced Cold Tumors by Pengwen Chen, Wenqian Yang, Koji Nagaoka, George Lo Huang, Takuya Miyazaki, Taehun Hong, Shangwei Li, Kazunori Igarashi, Kazuyoshi Takeda, Kazuhiro Kakimi, Kazunori Kataoka, Horacio Cabral

Get full text

From standard therapies to monoclonal antibodies and immune checkpoint inhibitors – an update for reconstructive surgeons on common oncological cases by Leonard Knoedler, Leonard Knoedler, Lioba Huelsboemer, Katharina Hollmann, Katharina Hollmann, Michael Alfertshofer, Konstantin Herfeld, Konstantin Herfeld, Helia Hosseini, Sam Boroumand, Viola A. Stoegner, Viola A. Stoegner, Ali-Farid Safi, Ali-Farid Safi, Markus Perl, Markus Perl, Samuel Knoedler, Samuel Knoedler, Bohdan Pomahac, Martin Kauke-Navarro

“…In the recent decade, novel non-surgical treatment strategies involving monoclonal antibodies (mAB) and immune checkpoint inhibitors (ICI) have been successfully incorporated into standard treatment algorithms. …”
Get full text

MCF-7 İnsan Meme Kanseri Hücre Soyunda Doksorubisin Öncesi ve Sonrası GST İzozimlerinin, İlaç Dirençlilik Proteinlerinin ve Apoptotik Etkisinin Araştırılması by Mustafa Türk, Gülçin Güler Şimşek, Serpil Oğuztüzün, Arzu Kaya Koçdoğan

Get full text

Mikrokalsifikasyonların Tanısında Vakum Destekli Stereotaktik Meme Biyopsisi:Üç Yıllık Deneyimlerimiz by Mustafa Koplay, Mahmut Çelik, Hasan Erdoğan, Alaaddin Nayman, Ali Sami Kıvrak, Seda Özbek

Get full text

Immunogenic Nanovesicle‐Tandem‐Augmented Chemoimmunotherapy via Efficient Cancer‐Homing Delivery and Optimized Ordinal‐Interval Regime by Mengchi Sun, Wen Shi, Yuxia Wu, Zhonggui He, Jin Sun, Shuang Cai, Qiuhua Luo

“…Abstract The strategy of combining immune checkpoint inhibitors (ICIs) with anthracycline is recommended by clinical guidelines for the standard‐of‐care treatment of triple‐negative breast cancer (TNBC). …”
Get full text

Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade by Xuewei Bai, Yanmei Zhou, Yuki Yokota, Yoshihiro Matsumoto, Bo Zhai, Nader Maarouf, Hikaru Hayashi, Rolf Carlson, Songhua Zhang, Aryanna Sousa, Bei Sun, Hossein Ghanbari, Xiaoqun Dong, Jack R. Wands

“…Abstract Background Interactions between tumor and microenvironment determine individual response to immunotherapy. Triple negative breast cancer (TNBC) and hepatocellular carcinoma (HCC) have exhibited suboptimal responses to immune checkpoint inhibitors (ICIs). …”
Get full text

Üçüncü Basamak Sağlık Kuruluşundaki Hemşirelerin Kanser Tarama Programları Bilgileri ile Tarama Testlerini Yaptırma Durumları by Neslihan ŞEKER, Yağmur KÖKSAL YASİN, Esma ÖZAYDIN, Burak ÇAPACI, Pınar OKYAY

Get full text

ANXIETY AND PAIN ASSOCIATED WITH PROCESS MAMMOGRAPHY: INFLUENCE OF PROCESS INFORMATION BEFORE by Meryem Yılmaz, Özlem Kıymaz

Get full text

Immune Checkpoint Inhibitors Combined with Targeted Therapy: The Recent Advances and Future Potentials by Bin Li, Juan Jin, Duancheng Guo, Zhonghua Tao, Xichun Hu

Get full text

CD20+CD22+ADAM28+ B Cells in Tertiary Lymphoid Structures Promote Immunotherapy Response by Zhenghao Wu, Zhenghao Wu, Junjie Zhou, Yunxiao Xiao, Jie Ming, Jing Zhou, Fang Dong, Xiaoqi Zhou, Zhuoshuo Xu, Xiangwang Zhao, Ping Lei, Tao Huang

“…Immunofluorescence confirmed the presence of BIR cells in tertiary lymphoid structures (TLSs) in skin SCC, RCC, CRC, and breast cancer. BIR-associated gene signatures correlate with positive outcomes in patients with melanoma, glioblastoma, NSCLC, HNSCC, or RCC treated with ICI therapy, and BIR-cell density predicted NSCLC patients’ response to checkpoint immunotherapy. …”
Get full text

Prognostic role of IL-8 in cancer patients treated with immune checkpoint inhibitors: a system review and meta-analysis by Dan Zou, Ailin Song, Wei Yong

Get full text

The role of radiotherapy in patients with refractory Hodgkin's lymphoma after treatment with brentuximab vedotin and/or immune checkpoint inhibitors by Ruizhi Zhao, Han Shao, Guiqing Shi, Yanyan Qiu, Tianlan Tang, Yuping Lin, Silin Chen, Cheng Huang, Siqin Liao, Jinhua Chen, Haiying Fu, Jianzhi Liu, Benhua Xu, Tingbo Liu, Yujing Zhang, Yong Yang

Get full text

Novel Biomarkers for Personalized Cancer Immunotherapy by Yoshitaro Shindo, Shoichi Hazama, Ryouichi Tsunedomi, Nobuaki Suzuki, Hiroaki Nagano

Get full text

Unraveling the role of M1 macrophage and CXCL9 in predicting immune checkpoint inhibitor efficacy through multicohort analysis and single‐cell RNA sequencing by Yunfang Yu, Haizhu Chen, Wenhao Ouyang, Jin Zeng, Hong Huang, Luhui Mao, Xueyuan Jia, Taihua Guan, Zehua Wang, Ruichong Lin, Zhenjun Huang, Hanqi Yin, Herui Yao, Kang Zhang

Get full text